Lupin Q3 Profit Jumps 37%! Is $1 Billion US Sales Next? | Margin Outlook & GLP-1 Big Bet | ET Now
Why It Matters
Lupin’s strong earnings and clarified US sales target signal robust growth potential, while its expanding GLP‑1 and biosimilar pipeline could boost margins and market share in a high‑growth therapeutic segment.
Key Takeaways
- •Q3 profit rose 37% to ₹1,175.5 crore in quarter
- •US sales on track to exceed $1 billion this year
- •EBITDA margin expected 27‑28% for full fiscal year
- •India formulation growth outpaced market at ~10% YoY
- •Robust pipeline includes GLP‑1 injectables, biosimilars, and novel products
Summary
Lupin reported a 37% jump in Q3 profit, reaching ₹1,175.5 crore, and reaffirmed its aim to cross $1 billion in U.S. sales this fiscal year. The company also lifted its full‑year EBITDA margin outlook to 27‑28%, up from the prior 29‑30% nine‑month range, citing steady top‑line growth and disciplined cost control.
Management highlighted that the lingering loss‑on‑exclusivity (LOE) impact in India is now behind them, with formulation sales growing 10.8% YoY, well ahead of the market. A settlement on the Mira‑Begron product removed litigation risk, and the tender business’s volatility was noted as the only drag on overall Indian growth.
CEO Vinita Gupta confirmed the $1 billion U.S. target, while CFO Romesh Swami emphasized margin resilience despite upcoming licensing fees. The executive team also detailed a busy launch calendar, including GLP‑1 injectables, a biosimilar pegulist, and several generics, positioning Lupin for sustained revenue expansion.
The earnings beat and clarified pipeline suggest Lupin is well‑placed to capitalize on the booming GLP‑1 market and broader cardio‑metabolic demand, offering investors confidence in continued top‑line momentum and margin expansion.
Comments
Want to join the conversation?
Loading comments...